DDInter1189 DDInter1376
Methylphenidate is a central nervous system stimulant used most commonly in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and for narcolepsy. Also known as the marketed products Ritalin, Concerta, or Biphentin, methylphenidate is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve the following group of developmentally inappropriate symptoms associated with ADHD: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. Long-acting formulations of psychostimulants such as methylphenidate,, and are considered the most effective and widely used treatment for ADHD, and are considered first-line options for children, adolescents, and adults as recommended by CADDRA (Canadian ADHD Resource Alliance). CADDRA recommends the use of methylphenidate due to long term studies, of over twenty years in duration, which show methylphenid
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Methylphenidate {u} (Compound) resembles {v} (Compound) Dexmethylphenidate
Methylphenidate {u} (Compound) resembles {v} (Compound) Homatropine Methylbromide
Methylphenidate {u} (Compound) binds {v} (Gene) SLC6A3
Methylphenidate {u} (Compound) palliates {v} (Disease) attention deficit hyperactivity disorder
Methylphenidate {u} (Compound) is included by {v} (Pharmacologic Class) Central Nervous System Stimulation
Methylphenidate {u} (Compound) causes {v} (Side Effect) Intoxication
Methylphenidate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Methylphenidate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Methylphenidate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenylephrine
Methylphenidate {u} may lead to a major life threatening interaction when taken with {v} Methylene blue
Methylphenidate (Compound) resembles Dexmethylphenidate (Compound)
Methylphenidate (Compound) resembles Homatropine Methylbromide (Compound)
Methylphenidate (Compound) binds SLC6A3 (Gene)
Methylphenidate (Compound) palliates attention deficit hyperactivity disorder (Disease)
Methylphenidate (Compound) is included by Central Nervous System Stimulation (Pharmacologic Class)
Methylphenidate (Compound) causes Intoxication (Side Effect)
Methylphenidate may cause a minor interaction that can limit clinical effects when taken with Warfarin
Methylphenidate may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Methylphenidate may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine
Methylphenidate may lead to a major life threatening interaction when taken with Methylene blue